Canagliflozin protects against hyperglycemia-induced cerebrovascular injury by preventing blood-brain barrier (BBB) disruption via AMPK/Sp1/adenosine A2A receptor.

MLA

Liu, Zhiyi, et al. “Canagliflozin Protects against Hyperglycemia-Induced Cerebrovascular Injury by Preventing Blood-Brain Barrier (BBB) Disruption via AMPK/Sp1/Adenosine A2A Receptor.” European Journal of Pharmacology, vol. 968, Apr. 2024, p. 176381. EBSCOhost, https://doi.org/10.1016/j.ejphar.2024.176381.

APA

Liu, Z., Hua, W., Jin, S., Wang, Y., Pang, Y., Wang, B., Zhao, N., Song, Y., & Qi, J. (2024). Canagliflozin protects against hyperglycemia-induced cerebrovascular injury by preventing blood-brain barrier (BBB) disruption via AMPK/Sp1/adenosine A2A receptor. European Journal of Pharmacology, 968, 176381. https://doi.org/10.1016/j.ejphar.2024.176381

Chicago

Liu, Zhiyi, Wei Hua, Sinan Jin, Yueying Wang, Yuxin Pang, Benshuai Wang, Nan Zhao, Yuejia Song, and Jiping Qi. 2024. “Canagliflozin Protects against Hyperglycemia-Induced Cerebrovascular Injury by Preventing Blood-Brain Barrier (BBB) Disruption via AMPK/Sp1/Adenosine A2A Receptor.” European Journal of Pharmacology 968 (April): 176381. doi:10.1016/j.ejphar.2024.176381.